2019-003334-16: Novel budenosid suppository in addition to basic therapy with oral mesalazine compared to basic therapy alone for treatment of ulcerative colitis |
|
|
| Not yet recruiting | 3 | 360 | Europe, RoW | Budenofalk® suppositories, Salofalk 3g gastro-resistant prolonged-release granules, Suppository, Gastro-resistant granules, Salofalk 3g gastro-resistant prolonged-release granules | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | acute ulcerative colitis, acute ulcerative colitis - inflammation and ulcers of the colon and rectum, Diseases [C] - Digestive System Diseases [C06] | | | | |
